Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: CGI-58(Comparative gene identification-58)/ABHD5 (α/β-hydrolase domain-containing 5) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 7/January/2017, 11.57 pm

Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: CGI-58(Comparative gene identification-58)/ABHD5 (α/β-hydrolase domain-containing 5) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 7/January/2017, 11.57 pm

Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: CGI-58(Comparative gene identification-58)/ABHD5 (α/β-hydrolase domain-containing 5) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 7/January/2017, 11.57 pm 150 150 Dr Boomi's Genom-2-Discovery Center

From Research findings to Therapeutic opportunity: 

The study presented here suggests that CGI-58/ABHD5, by increasing the expression of its target genes, it may: (i) decrease the expression of Dihydropyrimidine dehydrogenase (DPYD); (ii) increase 5-FU accumulation in cancer cells; (iii) augment and restore chemosensitivity in drug-resistant Human cancers; (iv) promote anti-tumor effect; and (v) enhance the efficacy of anticancer drug treatment.

price-5

[easy_payment currency=”USD”]

Thereby, it may inhibit proliferation, chemoresistance and apoptosis of cancer cells. Thus, pharmacological formulations encompassing “CGI-58/ABHD5 or its activators” may be used to inhibit cancer progression.

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Undisclosed information: How CGI-58/ABHD5 decreases the expression of Dihydropyrimidine dehydrogenase (DPYD)?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $5

For purchase and payment details, you may reach us at info@genomediscovery.org

References:  

Citation: Boominathan, L., Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: CGI-58(Comparative gene identification-58)/ABHD5 (α/β-hydrolase domain-containing 5) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 7/January/2017, 11.57 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Share
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Emodin (6-methyl-1,3,8-trihydroxy anthraquinone), found in Polygonum multiflorum, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 7/January/2017, 11.51 pm
Molecular therapy for triple-negative breast tumors: Lovastatin (brand name: Mevacor), a statin drug used in the treatment of hypercholesterolemia, increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 8/January/2017, 9.54 pm
Start Typing